ViennaLab Diagnostics GmbH

Predict the therapeutic response of antiviral therapy in Hepatitis C Virus (HCV) infected patients.

The IL28B RealFast™ Assay helps to predict the success of antiviral therapy and sustained virologic response (SVR) in Hepatitis C Virus (HCV) infected patients.

 

IL28B

 

  • Direct-acting antivirals and pegylated Interferon/Ribavirin regimens are used for the treatment of HCV infection.
  • SVR is dependent on virus genotype and on patients’ factors like age, sex, ethnicity and genetic variants associated with antiviral activity.
  • The functional variant rs368234815 TT>ΔG regulating IL28B expression is the strongest known host factor for predicting HCV clearance.
  • Genotyping of rs368234815 TT>ΔG helps to predict spontaneous and treatment-induced viral clearance in patients independent of their ethnicity.

 

ProductReg. Stat.REFUnit SizeIFUBrochure
IL28B RealFast™ Assay CE/IVD7-200
7-203		100 rxn
32 rxn

PDF

PDF

We use Matomo to analyze the access to our website. We pass on information about your use of our website to our partners for analysis. Our partners may combine this information with other data that you have provided to them or that they have collected as part of your use of the services. I agree.

Deny